| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3.0 | 3.3 |
| Gross profit | 1.5 | 1.6 |
| Profit before tax | -0.1 | -0.4 |
| Net income | -0.1 | -0.4 |
| EPS (diluted, $ a share) | $-0.00 | $-0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -7.0% |
|---|---|
| Gross margin | 50.0% |
| Operating margin | 12.5% |
10-Q filed with the SEC, OTC: CVSI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
CV Sciences, Inc.: key numbers
- Share price
- $0.0096Close, Nov 16
- Market cap
- $2.32M
- Shares outstanding
- 242.18MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from CV Sciences, Inc.
All →CV Sciences Insider Charlie E. Cheever III Buys $45.6K of Stock
Charlie E. Cheever III bought 4,557,721 shares of CV Sciences, Inc. at $0.01 a share, worth $45.6K in total between Nov 4, 2026 and Nov 9, 2026. Shares held after the trade: 31,706,432 (+6.7%).
- Value
- $45.6K
- Shares
- 4,557,721
- Average price
- $0.0100
- Holding change
- +6.7%
- Trade date
- Nov 4, 2026 to Nov 9, 2026
CV Sciences Financial Results
CV Sciences reported third quarter 2026 revenue of $3.0 million, a 7% decrease year-over-year due to restrictive regulations and lower sales volumes. Despite the revenue decline, the company achieved positive adjusted EBITDA of $32,000 and expanded gross margins to 50.0% through cost discipline and operational efficiency.
- Term
- Q3 2026
“Our third quarter results demonstrate continued progress in strengthening the operating performance of our business despite ongoing regulatory challenges and pressure on revenue. We expanded gross margins to 50.0%, reduced operating expenses by 11.6% year over year, and achieved positive adjusted EBITDA of $32,000, compared to adjusted EBITDA losses in both the prior-year quarter and the second quarter of 2026.”
Joseph Dowling, Chief Executive Officer
“Looking ahead, we remain focused on strengthening our established brands, expanding our presence in broader science-based wellness categories, maintaining disciplined capital allocation, and pursuing strategic opportunities that support sustainable growth and long-term shareholder value.”
Joseph Dowling, Chief Executive Officer
CV Sciences Court & Legal Update
CV Sciences has settled an arbitration case initiated in February 2025 against its former legal counsel. Under the settlement terms, the company received $500,000 and both parties have mutually released all claims against each other.
- Counterparty
- former legal counsel